Navigation Links
Pfizer Completed Acquisition of FoldRx
Date:10/6/2010

NEW YORK, Oct. 6 /PRNewswire-FirstCall/ -- Pfizer (NYSE: PFE) today announced the completion of its acquisition of FoldRx Pharmaceuticals, Inc., a privately held drug discovery and clinical development company.

FoldRx Pharmaceuticals, Inc. is now a wholly owned subsidiary of Pfizer Inc.  

(Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20100416/PFIZERLOGO)

Pfizer Inc: Working together for a healthier world™

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life.  We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals.  Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products.  Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world.  For more than 150 years, Pfizer has worked to make a difference for all who rely on us.  To learn more about our commitments, please visit us at www.pfizer.com

More information is available at www.pfizer.com.  

Follow Pfizer on www.Twitter.com/pfizer_news.


'/>"/>
SOURCE Pfizer Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Pfizer To Review Strategic Alternatives For Capsugel
2. Pfizer Offers First 500,000 Consumers Free Advil® to Launch Medicine Cabinet Cleanout Campaign
3. Pfizer Invites Public to View and Listen to Webcast of November 2 Conference Call With Analysts
4. Pfizer Discontinues Phase 3 Trial of SUTENT® in Advanced Castration-Resistant Prostate Cancer
5. Updated Pfizer Pipeline Focuses on Value, Unmet Medical Need
6. Reportlinker Adds Pfizer Inc.: PharmaVitae Profile
7. Amgen and Pfizer Introduce Psophisticated Style: A Guide to Everyday Style and Psoriasis™ Hosted by Tim Gunn
8. Pfizer to Acquire FoldRx Pharmaceuticals
9. World Health Organization Grants Prequalification to Prevenar 13*, Pfizers 13-valent Pneumococcal Conjugate Vaccine for Infants and Young Children
10. Conatus Pharmaceuticals Acquires Pfizers Idun Subsidiary
11. Pfizer Suspends Chronic Pain Studies in Tanezumab Clinical Trial Program; Some Studies Continue in Areas of Unmet Medical Need
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... --  Risperdal lawsuits involving gynecomastia (male breast growth) ... the atypical antipsychotic medication continue to move forward in ... Pleas, where the state,s Risperdal docket has been centralized ... posted on the Court,s website , the litigation ... 2017 at 11:00 a.m. (In Re: Risperdal Litigation, Case ...
(Date:2/17/2017)... NEW YORK , Feb. 17, 2017 /PRNewswire/ ... announced today the partnership of their 3D body ... in healthcare IT.  The new integration will be ... on an interactive model of the human body. ... data saves clinicians time, while also increasing the ...
(Date:2/16/2017)... , Feb. 16, 2017 Research and ... for Emerging Medical Device Technologies" report to their offering. ... ... open procedures, general instruments, non-drug coated implantables, large endoscopes, needle ... in use over the last two to three decades for ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... February 17, 2017 , ... Like most hospitals across ... Driven in large part by the Hospital Readmission Reduction Program (HRRP), the return of ... focus area for hospitals across the nation. While many providers are struggling to leverage ...
(Date:2/17/2017)... ... February 17, 2017 , ... The Mason ... to families and business owners in and around the Hampton Roads metropolitan region, ... prevent all forms of domestic violence. , There are multiple categories of domestic ...
(Date:2/16/2017)... ... February 17, 2017 , ... Harsha ... 10 years of research, development and clinical trials, the founder of Chigurupati Technologies ... patented compound of FDA approved ingredients that when infused into alcohol, protect the ...
(Date:2/16/2017)... ... 17, 2017 , ... Teaching nursing care of vulnerable children is the focus ... is being created with the support of the Hearst Foundations. An initiative of the ... address what has been identified as a critical gap in preparing the next generation ...
(Date:2/16/2017)... (PRWEB) , ... February 16, 2017 , ... ... nursing professionalism, teamwork and superiority in patient care, NWH has achieved Magnet® ... on Magnet on Tuesday, January 31, 2017. The American Nurses Credentialing Center’s Magnet ...
Breaking Medicine News(10 mins):